WHAT IS CANNABIGEROLIC ACID MONOETHEYL ETHER (CBGAM)?
CBGs are cannabinoids produced by the cannabis and marijuana plant. Just like CBD, they have non-psychoactive property. A member of the CBGs is Cannabigerolic acid monomethyl ether (CBGAM).
There is no accurate record of when CBGAM was discovered. But since it is one of the CBGs, one can assume they share the same discovery date. In 1964, researchers Yehiel Gaoni and Raphael Mechoulam discovered CBG, a compound isolated from Hashish. They also discovered that Cannabigerolic Acid (CBGA) is the primary cannabis formed in the cannabis plant.
So far there is not much information available about CBGAM, but original cannabinoids like CBDA, THCA, CBCA, and CBGMA are isolated using a simple column technique called chromatographic from a clean domestic cannabis strain.
There is a restriction in the study of cannabis because of its psychoactive effects. CBGAM is at its initial stage of research and development. Almost every compound present in the cannabis plant is known to have distinctive properties that are useful for the human body. We hope to have more research on CBGAM that will help to fully understand the compound and its effects.
HOW DOES CBGAM WORK?
There is little to no accurate reporting on how CBGAM works in the body. But since CBGAM belongs to the CBGs, there is a chance that CBGAM might have a mechanism associated with CBG. Just as it is with other cannabinoids, CBGs functions by impacting the Endocannabinoid System (ECS). Endocannabinoids are produced naturally by the body, and they are responsible for the regulation of physiological functions and maintenance of internal balance. Although the method of the mechanism is still unknown, researchers speculate that CBG may have a different way of interacting with cannabinoid receptors.
POSSIBLE THERAPEUTIC BENEFITS
Since Cannabigerolic acid Monomethyl ether (CBGAM) belongs to the category of the CBGs, there are chances that CBGAM might have similar therapeutic/medicinal benefits to CBG. Most of the studies performed on CBG were done on lab animals and not humans. But there are reasons to believe that the compound might have similar effects when used on human beings.
CBG a non-psychoactive compound is reported to be an analgesic, anti-inflammatory, anti-cancer, and be able to reduce nausea. It has also been reported to treat glaucoma by reducing painful intraocular eye pressure. A research carried out on rat models showed CBG protecting against neurodegenerative diseases like Huntington’s diseases. Another promising use of CBG is in the treatment of Inflammatory Bowel Diseases (IBDs); ulcerative colitis and Crohn’s disease.
Since Cannabigerolic acid Monomethyl ether (CBGAM) belongs to the category of the CBGs, there are chances that CBGAM might have similar therapeutic/medicinal benefits to CBG.
Valdeolivas S., et al, Neuroprotective properties of cannabigerol in Huntington’s disease: studies in R6/2 mice and 3-nitropropionate lesioned mice. Neurotherapeutics. 2015 Jan;12(1):185-99. doi: 10.1007/s13311-014-0304-z.
Colasanti, BK., A Comparison of the Ocular and Central Effects of Δ9-Tetrahydrocannabinol and Cannabigerol. Journal of Ocular Pharmacology and TherapeuticsVol. 6, No. 4.#
Borellis, F. et al, Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis derived non-psychotropic cannabinoid. Carcinogenesis, Volume 35, Issue 12, December 2014, Pages 2787–2797,